EFTA Document EFTA01583221
Summary
Ask AI About This Document
Extracted Text (OCR)
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
302.634-55809824976Related Documents (6)
EFTA Document EFTA01361145
Growth Strategy returns Performance' for taxable client ending 3/31/15 CIO Strategies w/ U.S. Core Equity as U.S. Large Cap Vehicle ® Blended Benchmark 6 - 4 2 - 0 3.51 1.93 1Q15 C [0 Strategies .. Growth Blended Benchmark 9.78 8.30 8.42 4.15 1 Year 9.27 7.98 3 Year 5 Year °A Annualized Performance Gross of Fees 7.35 5.88 10 Year 7.07 2014 2013 2012 2011 2010 2009 2008 2007 4.84% 17.64% 14.43-;•:.. -2.94% 13.79% 29.09% 30.42% 12.52% 3.40% 16.25% 1
Glossary of Fiscal and Health Terms from House Oversight Document
The passage consists solely of generic definitions and terminology related to fiscal policy, government accounting, and health care. It contains no specific actors, transactions, dates, or allegations Provides basic definitions of fiscal year, GDP price index, General Fund, and GSEs. Describes the Independent Payment Advisory Board (IPAB) and its role under the PPACA. Outlines labor force metrics
EFTA Document EFTA01299130
KYC Print Page 1 of' 19 DB PWM GLOBAL KYC/NCA: PART A Int KYC Case # : 01141308 One sheet must be established per relationship - list all accounts included in the relationship 1. Relationship Details Relationship Name: EPSTEIN, JEFFREY RELATIONSHIP:00000483290 Booking Center: New York Relationship Manager: Paul Moms Relationship to PWM: 17 New PWM Relationship F Existing PWM Relationship If existing, please indicate since when the relationship exists, provide reason for new profi
Industry overview of Curaleaf, CV Sciences, Elixinol, and Green Thumb Industries CBD product lines (Feb 2019)
Industry overview of Curaleaf, CV Sciences, Elixinol, and Green Thumb Industries CBD product lines (Feb 2019) The passage provides a market‑focused summary of several publicly traded cannabis/MSO companies and their product expansions. It contains no specific allegations, financial flows, or connections to high‑level officials, but it does mention revenue figures and growth rates that could be useful for baseline industry analysis. Because it lacks any reference to powerful actors, controversial actions, or actionable leads, its investigative value is limited. Key insights: Curaleaf launched a CBD line sold in 47 states, targeting pharmacy chains and grocery stores.; Curaleaf reported ~$45 M revenue for FY9M18 with 247% YoY growth and 57% gross margin.; CV Sciences’ PlusCBD Oi! brand generated ~$34 M revenue FY9M18, 153% YoY growth, 72% gross margin.
EFTA Document EFTA01364547
GLOUS238 SOUTHERN FINANCIAL LLC SOF IV — Project Klein Exclusive deal Expected Glosing Date: June 2018 El Fund Secondary i Secondary K Single Asset Deal Seller type: Alternative funds Key investment data Transaction summary Invested Capital at dose E60-100m (US$80-120m) Number of companies 4 Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Business services / Healthcare services
EFTA Document EFTA01282879
Deutsche Asset & Wealth Management DBTCA Deposit Account Opening Application Private Wealth Premium!" Elite Personal Accounts Checking Acct. I O Elite C • • Acct. APY O Elite Mono Market Do os Acct. APY O Certificate of Deposit Acct. I APY Term O DB AG NY Preferred Certificate of Deposit Met. N APY Term Promo term 108TCA deposit account required, along with a DO AG Prelersed 'Terms and Conditions) Private Wealth Premium^. Internet Banking Services O O9 Private Wea
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.